Venous thromboembolism (VTE) encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE). Each year, VTE affects about 300 000 to 600 000 people in the United States, and death is the first manifestation in one-fourth of this population.1{Beckman, 2010 #79} Moreover, approximately 10% of the US population has genetic factors that increase their risk for developing thrombosis.1 In addition to inherited disorders, factors that contribute to VTE include prolonged immobilization, trauma, surgery, cancer, and critically ill patients.2 Routine assessment and prophylaxis are recommended in these groups to avoid DVT-related complications.2 Anticoagulants are the mainstay of drugs used in DVT/PE prevention and treatment. Despite the availability of evidence-based guidelines for anticoagulant therapy, there is suboptimal implementation of DVT prophylaxis in hospitalized patients.3 All anticoagulants are “high-alert” drugs, and judicious use is mandatory to prevent bleeding complications.4 This review discusses treatment guidelines, monitoring, side effects, and reversal agents available for some anticoagulant drugs approved for VTE. Dissemination of the knowledge via pharmacy education programs significantly improves the adherence to VTE prophylaxis.5 Understanding the clinical aspects of anticoagulant dispensing as presented in this review is hoped to facilitate implementation of the theoretical knowledge as well as evidence-based guidelines in order to maximize patient benefit.
BeckmanMGHooperWCCritchleySEVenous thromboembolism: a public health concern. Am J Prev Med. 2010;38(4 suppl):S495–S501.
2.
GeertsWHBergqvistDPineoGFPrevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 suppl):381S–453S.
3.
StinnettJMPendletonRSkordosLVenous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. Am J Hematol. 2005;78(3):167–172.
4.
CundiffDK. A systematic review of Cochrane anticoagulation reviews. Medscape J Med. 2009;11(1):5.
5.
DobeshPPStacyZA. Effect of a clinical pharmacy education program on improvement in the quantity and quality of venous thromboembolism prophylaxis for medically ill patients. J Manag Care Pharm. 2005;11(9):755–762.
6.
HolbrookASchulmanSWittDMEvidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e152S–e184S.
7.
WolframRMatthiasR. Regulation of Tissue Factor Expression. Austin, TX: Landes Bioscience and Springer Science+Business Media; 2000.
8.
RolandoRPerumalT. Platelet-Vessel Wall Interactions in Hemostasis and Thrombosis. San Rafael, CA: Morgan & Claypool Life Sciences; 2010.
9.
PhilipWMGeorgeJBJosephPMAnticoagulant, Thrombolytic, and Antiplatelet Drugs. IX ed., 1996.
10.
DipiroJTTalbertRLYeeGCPharmacotherapy: A Pathophysiologic Approach. 8th ed., 2006.
11.
Preventing errors relating to commonly used anticoagulants. Sentinel Event Alert. 2008;(41):1–4.
12.
DesaiUR. New antithrombin-based anticoagulants. Med Res Rev. 2004;24(2):151–181.
13.
Lexi-Comp OnlineTM Lexi-Comp Inc.
14.
LongoDLFauciASKasperDLHarrison's Principles of Internal Medicine. 18 ed. New York, NY: The McGraw Hill Company.
HackeWKasteMBluhmkiEThrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–1329.
17.
HirshJGuyattGAlbersGWExecutive summary: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 suppl):71S–109S.
18.
GeertsWHPineoGFHeitJAPrevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):338S–400S.
19.
NutescuEA. Assessing, preventing, and treating venous thromboembolism: evidence-based approaches. Am J Health Syst Pharm. 2007;64(11 suppl 7):S5–S13.
20.
HirshJWarkentinTEShaughnessySG. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 suppl):64S–94S.
21.
NugentMA: Chemistry & Biology of Heparin and Heparan sulfate, 2005.
22.
GarciaDABaglinTPWeitzJIParenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e24S–e43S.
23.
RosenbergAFZumbergMTaylorLThe use of anti-Xa assay to monitor intravenous unfractionated heparin therapy. J Pharm Pract. 2010;23(3):210–216.
24.
GuervilDJRosenbergAFWintersteinAGActivated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother. 2011;45(7-8):861–868.
25.
TahirR.A Review of unfractionated heparin and its monitoring. US Pharm. 2007;32:HS26–HS36.
26.
WarkentinTE.Heparin-induced thrombocytopenia. In: GinsbergJKearonCHirshJ, ed. Critical Decisions in Thrombosis and hemostasis.: B.C. Decker Inc.,; 1998.
27.
WarkentinTEAirdWCRandJH. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2003:497–519.
28.
LoGKJuhlDWarkentinTEEvaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759–765.
GuyattGHAklEACrowtherMExecutive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):7S–47S.
31.
LeeAYLevineMNBakerRILow-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–153.
32.
LinkinsLADansALMooresLKTreatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e495S–e530S.
CockcroftDWGaultMH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
35.
NutescuEASpinlerSAWittkowskyALow-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43(6):1064–1083.
36.
Fragmin (dalteparin) [package insert]. New York City, NY: Pfizer; 2009.
37.
HirshJ. New anticoagulants. Am Heart J. 2001;142(2 suppl):S3–S8.
38.
HirshJDalenJAndersonDROral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(1 suppl):8S–21S.
39.
NutescuEABathijaSSharpLKAnticoagulation patient self-monitoring in the United States: considerations for clinical practice adoption. Pharmacotherapy. 2011;31(12):1161–1174.
40.
du BreuilALUmlandEM. Outpatient management of anticoagulation therapy. Am Fam Physician. 2007;75(7):1031–1042.
41.
Garcia-AlaminoJMWardAMAlonso-CoelloP. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev. 2010;(4):CD003839.
42.
BloomfieldHEKrauseAGreerNMeta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med. 2011;154(7):472–482.
43.
HeneghanCAlonso-CoelloPGarcia-AlaminoJMSelf-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet. 2006;367(9508):404–411.
44.
GarciaDASchwartzMJ. Warfarin therapy: tips and tools for better control. J Fam Pract. 2011;60(2):70–75.
45.
Clinicaltrials.gov: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate, 2005.
46.
CottonBAMcCarthy JJHolcombJB. Acutely injured patients on dabigatran. N Engl J Med. 2011;365(21):2039–2040.
47.
EerenbergESKamphuisenPWSijpkensMKReversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–1579.
KakkarAKBrennerBDahlOEExtended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31–39.
50.
ErikssonBIBorrisLCFriedmanRJRivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765–2775.
51.
LassenMRAgenoWBorrisLCRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776–2786.
52.
PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
53.
Argatroban [package insert]. Research Triangle Park, NC: Glaxo Smithkline; 2009.
54.
KiserTHBurchJCKlemPMSafety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2008;28(9):1115–1124.
55.
KushnerFGHandM, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54(23):2205–2241.
56.
BittlJAChaitmanBRFeitFBivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142(6):952–959.
57.
StoneGWWhiteHDOhmanEMBivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007;369(9565):907–919.
58.
AndersonJLAdamsCDAntmanEMACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):e1–e157.
59.
StoneGWMcLaurinBTCoxDABivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21):2203–2216.
60.
TsuLVDagerWE. Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia. Ann Pharmacother. 2011;45(10):1185–1192.
